Web Analytics Made Easy - StatCounter
Tag

Adolescent

Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis.

By | Behavioral Health, Schizophrenia Spectrum

Authors: Antti Mustonen, Solja Niemelä, Tanja Nordström, Graham K. Murray, Pirjo Mäki, et al
The British Journal of Psychiatry, April 2018

BACKGROUND: The association between cannabis use and the risk of psychosis has been studied extensively but the temporal order still remains controversial. Aims To examine the association between cannabis use in adolescence and the risk of psychosis after adjustment for prodro…

Read More

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018

Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

Read More

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.

By | Brain Disorders, Epilepsy, Nervous System Diseases

Authors: José A. S. Crippa, Ana C. S. Crippa, Jaime E. C. Hallak, Rocio Martín-Santos, Antonio W. Zuardi
Frontiers in Pharmacology, 30 September 2016

Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the c…

Read More

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.

By | Brain Disorders, Epilepsy, Nervous System Diseases

Authors: Alexandra L. Geffrey, Sarah F. Pollack, Patricia L. Bruno, Elizabeth A. Thiele
Epilepsia, August 2015

OBJECTIVE: Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. Of the 25 subjects in the trial, 13 were being treated with clobazam (CLB). Because CLB and CBD are…

Read More

Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.

By | Adolescent, Medical Cannabis

Authors: Deborah S. Hasin, Melanie Wall, Katherine M. Keyes, Magdalena Cerdá, John Schulenberg, et al
The Lancet Psychiatry, July 2015

BACKGROUND: Adolescent use of marijuana is associated with adverse later effects, so the identification of factors underlying adolescent use is of substantial public health importance. The relationship between US state laws that permit marijuana for medical purposes and adoles…

Read More

Use of cannabis in severe childhood epilepsy and child protection considerations.

By | Brain Disorders, Epilepsy, Nervous System Diseases

Authors: Megan Yap, Laura Easterbrook, Jan Connors, Laura Koopmans
Journal of Paediatrics and Child Health, May 2015

The use of medical cannabis in chronic illness is increasingly investigated, yet little is known about its use in paediatric populations. As child protection clinicians are often asked to provide advice around whether parents’ actions to give medical cannabis to their chronica…

Read More

The impact of marijuana policies on youth: clinical, research, and legal update.

By | Legalization, Medical Cannabis, Pediatrics

Authors: COMMITTEE ON SUBSTANCE ABUSE, COMMITTEE ON ADOLESCENCE
Pediatrics, March 2015

This policy statement is an update of the American Academy of Pediatrics policy statement “Legalization of Marijuana: Potential Impact on Youth,” published in 2004. Pediatricians have special expertise in the care of children and adolescents and may be called on to advise legi…

Read More

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

By | Brain Disorders, Epilepsy, Nervous System Diseases

Authors: Brenda E. Porter, Catherine Jacobson
Epilepsy & Behavior, December 2013

Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in ch…

Read More

School achievement in 14-year-old youths prenatally exposed to marijuana.

By | Pediatrics, Pregnancy

Authors: Lidush Goldschmidt, Gale A. Richardson, Jennifer A. Willford, Stevan G. Severtson, Nancy L. Day
Neurotoxicology and Teratology, January-February 2012

The relation between prenatal marijuana exposure (PME) and school achievement was evaluated in a sample of 524 14-year-olds. Women were recruited during pregnancy and assessed, along with their offspring, at multiple phases from infancy to early adulthood. The sample represent…

Read More

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

By | Anxiety Disorders

Authors: Mateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, Danielle Chaves Gomes de Oliveira, Bruno Spinosa De Martinis, Flávio Kapczinski, João Quevedo, et al.
Neuropsychopharmacology, May 2011

Generalized Social Anxiety Disorder (SAD) is one of the most common anxiety conditions with impairment in social life. Cannabidiol (CBD), one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. This preli…

Read More